Bluebird bio (BLUE) reported quarterly earnings after the bell. As we’ve said before, this will be a quiet year for the company, with the exception of interim data from the ongoing STARBEAM study in cerebral adrenoleukodystrophy (CALD), which is due in April at the American Society of Neurology (AAN) annual meeting (April 15-21).
Of note, the company ended 2015 with $865.8 million in cash/equivalents, enough to fund operations through 2018, a testament to and result of the 3-year bull market and wide-open financing period in biotech. For a mid-stage company, bluebird is extremely well-funded.
Already a Premium user? Sign In
